Clinical Oncology and Cancer Research最新文献_第3页

Correlation between the number of metastasized lymph node groups and the prognosis of gastric cancer patients 胃癌患者转移淋巴结组数与预后的关系

Clinical Oncology and Cancer Research Pub Date : 2014-11-15 DOI: 10.3969/J.ISSN.1000-8179.20141127

Bofei Li, Wei Wang, Y. Li, Sharvesh Raj Seeruttun, Y. Zhan, Zhiwei Zhou

引用次数: 0

Clinical efficacy of pegaspargase plus GEMOX regimen for initial treatment of nasal NK/T-cell lymphoma pegaspargase联合GEMOX方案初始治疗鼻腔NK/ t细胞淋巴瘤的临床疗效

Clinical Oncology and Cancer Research Pub Date : 2014-10-15 DOI: 10.3969/J.ISSN.1000-8179.20140997

S. Liang, Hua-qing Wang, Huilai Zhang, Z. Qian, Shi-yong Zhou, Jing Zhao, Xia Liu

{"title":"Clinical efficacy of pegaspargase plus GEMOX regimen for initial treatment of nasal NK/T-cell lymphoma","authors":"S. Liang, Hua-qing Wang, Huilai Zhang, Z. Qian, Shi-yong Zhou, Jing Zhao, Xia Liu","doi":"10.3969/J.ISSN.1000-8179.20140997","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20140997","url":null,"abstract":"Objective: To evaluate the efficacy and safety of pegaspargase plus GEMOX (pegaspargase, gemcitabine, oxaliplatin) regimen in the initial treatment of nasal NK/T-cell lymphoma. Methods: Twelve preliminarily diagnosed nasal NK/T-cell lymphoma patients in Tianjin Medical University Cancer Institute and Hospital from June 2011 to March 2012 were analyzed. All patients took the pegaspargase plus GEMOX regimen (gemcitabine 800-1 000 mg/m on days 1 and 8, oxaliplatin 130 mg/m on day 1, and pegaspargase 2 500 IU/m on day 2), every three weeks for one cycle. The efficacy and toxicity of the regimen were evaluated in the follow-up treatment. Results: After two cycle treatments, 1 patient dropped out of treatment because of acute pancreatitis; the remaining 11 patients had response, in which 1 achieved complete response , 7 had partial response, 2 had stable disease, and 1 had progressive disease. The objective response rate was 72.7%, and the disease control rate was 90.9%. The 2-year overall survival rate was 90.9%. With median 6-cycle P-GEMOX regimen treatment, 81.8% of 11 patients presented side effects, primarily myelosuppression and hepatic dysfunction. Conclusion: Pegaspargase plus GEMOX regimen showed high efficacy on the initial treatment of nasal NK/T-cell lymphoma patients, but the incidence of adverse effect was still high.","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134562165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Perfusion computed tomography permits the assessment of non-small-cell lung cancer treated with anti-angiogenic therapy 灌注计算机断层扫描允许评估抗血管生成治疗的非小细胞肺癌

Clinical Oncology and Cancer Research Pub Date : 2014-10-15 DOI: 10.3969/J.ISSN.1000-8179.20140253

Hongren Wang, Zhaoxiang Ye

引用次数: 0

Bendamustine hydrochloride in patients with rituximab-refractory indolent B-cell non-Hodgkin's lymphoma 盐酸苯达莫司汀治疗利妥昔单抗难治性无痛b细胞非霍奇金淋巴瘤

Clinical Oncology and Cancer Research Pub Date : 2014-10-15 DOI: 10.3969/J.ISSN.1000-8179.20141005

Qiaoyun Min, Hua-qing Wang, Z. Qian, Huilai Zhang, Shi-yong Zhou, L. Qiu, Z. Song, J. Zhao, Xia Liu

引用次数: 0

Mechanisms of histone deacetylase inhibitor in treating T-cell lymphoma and related clinical trials 组蛋白去乙酰化酶抑制剂治疗t细胞淋巴瘤的机制及相关临床试验

Clinical Oncology and Cancer Research Pub Date : 2014-10-15 DOI: 10.3969/J.ISSN.1000-8179.20141434

Huilai Zhang, Hui-juan Lv, Hua-qing Wang

引用次数: 0

Radiation physics, quality control, and quality assurance of lung cancer brachytherapy with 125I particles 125I粒子肺癌近距离放射治疗的放射物理、质量控制和质量保证

Clinical Oncology and Cancer Research Pub Date : 2014-09-30 DOI: 10.3969/J.ISSN.1000-8179.20140924

Xiao-dong Li, Zun-cheng Zhang, Guangjun Zheng, Yongtao Guo, J. Chang, Ping Wang

引用次数: 1

Relationship between serum carcinoembryonic antigen level and epidermal growth factor receptor mutations and prognosis in resected non-small cell lung cancer 非小细胞肺癌切除术后血清癌胚抗原水平与表皮生长因子受体突变及预后的关系

Clinical Oncology and Cancer Research Pub Date : 2014-09-15 DOI: 10.3969/J.ISSN.1000-8179.20131740

Lianmin Zhang, Ligang Hao, Hua Zhang, Liuwei Gao, Daowei Wang, Zhenfa Zhang, Changli Wang

引用次数: 0

Research progress into Castleman disease Castleman病的研究进展

Clinical Oncology and Cancer Research Pub Date : 2014-09-15 DOI: 10.3969/J.ISSN.1000-8179.20140851

Qingqing Chen, Huilai Zhang, Hua-qing Wang

引用次数: 0

Research progress of autophagy in gastric cancer 胃癌自噬的研究进展

Clinical Oncology and Cancer Research Pub Date : 2014-08-30 DOI: 10.3969/J.ISSN.1000-8179.20140297

Xingming Xie, J. Deng, H. Liang

引用次数: 1

Treatment of malignant paravertebral and mesenchymal tumor pain with cryoablation 冷冻消融治疗恶性椎旁及间质肿瘤疼痛

Clinical Oncology and Cancer Research Pub Date : 2014-08-30 DOI: 10.3969/J.ISSN.1000-8179.20140204

Yong Li, Zhi Guo, W. Xing, Hai Tao Wang, Xueling Yang, Chang-fu Liu

{"title":"Treatment of malignant paravertebral and mesenchymal tumor pain with cryoablation","authors":"Yong Li, Zhi Guo, W. Xing, Hai Tao Wang, Xueling Yang, Chang-fu Liu","doi":"10.3969/J.ISSN.1000-8179.20140204","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20140204","url":null,"abstract":"Objective: This study aimed to analyze the feasibility, safety, and efficacy of cryoablation in treating pain caused by malignant paravertebral and mesenchymal tumor. Methods: Cryoablation was performed in 31 patients with unresectable and painful malignant paravertebral and mesenchymal tumors whose pain was poorly controlled by conventional treatment methods. Tumors ranged in size from 3 cm to 20 cm. Pain experienced by the patient was assessed using the Brief Pain Inventory (BPI) at 0, 1 day, 1 week, 1 month, and 3 months post-cryoablation. Results: BPI scores were divided into two categories, i.e., the influence and the se- verity of pain. Both categories showed downward trend after cryoablation. Pain severity score significantly decreased (P=0.001, t= 3.862; P=0.031, t=2.261) 1 day and 1 month after cryoablation. Pain influence score also significantly decreased (P=0.016, t=2.566; P= 0.036, t=2.195) 1 day and 1 week after cryoablation. Two patients (6.45%) had mild complications, and no serious complication was ob- served. Conclusion: Cryoablation is a low-risk and well-tolerated topical treatment for pain caused by unresectable malignant paraverte- bral and mesenchymal tumors.","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2014-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127282697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0